ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing
ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing
About this item
Full title
Author / Creator
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Tumour-specific T cells have the potential to eradicate cancer. However anti-tumour immunity is limited by low TCR affinities, MHC downregulation by cancer cells and an immunosuppressive tumour microenvironment. As most tumour-associated antigens are auto-antigens, tumour specific T cells with high affinity TCRs are likely to be deleted in the thym...
Alternative Titles
Full title
ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4649398
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4649398
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1186/2051-1426-3-S2-P299
